---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-086992"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:48:30.697002+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ironwood Q2 revenue down 12% to $94.4M; cuts FY 2024 guidance on Medicaid pricing

## Summary
- Total revenue $94.4M in Q2 2024, down 12% from $107.4M in Q2 2023; FY 2024 guidance revised lower due to pricing pressure.
- LINZESS prescription demand up 11% YoY but Medicaid utilization drove pricing headwinds; new-to-brand growth 15%.
- GAAP net loss of $0.9M (($0.01)/share) vs $1.06B loss in Q2 2023; adjusted EBITDA of $27.9M vs $(1.03B) last year.
- Plans to pursue apraglutide rolling NDA for short bowel syndrome; expects submission in Q1 2025. CNP-104 topline results on track for Q3 2024.

## SEC filing metadata
- accession: 0001104659-24-086992
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465924086992/0001104659-24-086992-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465924086992/tm2421104d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-086992
- JSON: https://secwatch.observer/filing/0001104659-24-086992.json
- Plain text: https://secwatch.observer/filing/0001104659-24-086992.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.